Concepts (240)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 38 | 2024 | 362 | 4.900 |
Why?
|
| Brain Neoplasms | 38 | 2024 | 647 | 4.060 |
Why?
|
| Deep Brain Stimulation | 14 | 2023 | 49 | 2.440 |
Why?
|
| Meningioma | 7 | 2024 | 58 | 1.380 |
Why?
|
| Meningeal Neoplasms | 7 | 2024 | 50 | 1.350 |
Why?
|
| Parkinson Disease | 6 | 2024 | 89 | 1.170 |
Why?
|
| Alzheimer Disease | 6 | 2014 | 302 | 1.120 |
Why?
|
| Retrospective Studies | 37 | 2024 | 3708 | 0.940 |
Why?
|
| Radiation Injuries | 3 | 2023 | 78 | 0.940 |
Why?
|
| Treatment Outcome | 33 | 2024 | 3460 | 0.930 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2024 | 384 | 0.880 |
Why?
|
| Humans | 79 | 2024 | 32968 | 0.810 |
Why?
|
| Middle Aged | 50 | 2024 | 12203 | 0.720 |
Why?
|
| Trigeminal Neuralgia | 3 | 2019 | 33 | 0.720 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2024 | 80 | 0.700 |
Why?
|
| Fornix, Brain | 4 | 2014 | 7 | 0.690 |
Why?
|
| Brain | 6 | 2023 | 949 | 0.660 |
Why?
|
| Neurons | 2 | 2014 | 417 | 0.640 |
Why?
|
| Laser Therapy | 5 | 2023 | 56 | 0.620 |
Why?
|
| Salvage Therapy | 11 | 2020 | 134 | 0.620 |
Why?
|
| Male | 52 | 2024 | 19754 | 0.610 |
Why?
|
| Adult | 34 | 2024 | 9586 | 0.600 |
Why?
|
| Female | 52 | 2024 | 20375 | 0.600 |
Why?
|
| Aged | 40 | 2024 | 10637 | 0.600 |
Why?
|
| Glioblastoma | 5 | 2020 | 157 | 0.580 |
Why?
|
| Dopamine | 6 | 2024 | 234 | 0.520 |
Why?
|
| Emotions | 3 | 2024 | 59 | 0.490 |
Why?
|
| Gyrus Cinguli | 2 | 2013 | 22 | 0.480 |
Why?
|
| Cranial Irradiation | 6 | 2020 | 93 | 0.480 |
Why?
|
| Epilepsy, Temporal Lobe | 3 | 2023 | 7 | 0.480 |
Why?
|
| Depressive Disorder, Major | 2 | 2013 | 41 | 0.470 |
Why?
|
| Aged, 80 and over | 22 | 2024 | 4065 | 0.470 |
Why?
|
| Lung Neoplasms | 5 | 2024 | 429 | 0.440 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2014 | 7 | 0.440 |
Why?
|
| Electric Stimulation Therapy | 1 | 2014 | 14 | 0.440 |
Why?
|
| Cerebral Cortex | 2 | 2021 | 126 | 0.440 |
Why?
|
| Basal Ganglia | 1 | 2014 | 16 | 0.430 |
Why?
|
| Memory | 2 | 2012 | 191 | 0.420 |
Why?
|
| Thalamus | 1 | 2014 | 33 | 0.420 |
Why?
|
| Magnetic Resonance Imaging | 11 | 2023 | 1310 | 0.420 |
Why?
|
| Neurosurgical Procedures | 4 | 2021 | 100 | 0.420 |
Why?
|
| Corpus Striatum | 3 | 2020 | 62 | 0.410 |
Why?
|
| Memory Disorders | 2 | 2010 | 54 | 0.400 |
Why?
|
| Hippocampus | 5 | 2018 | 171 | 0.390 |
Why?
|
| Follow-Up Studies | 13 | 2022 | 2287 | 0.390 |
Why?
|
| Glioma | 3 | 2021 | 136 | 0.390 |
Why?
|
| Prefrontal Cortex | 1 | 2013 | 72 | 0.380 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2024 | 113 | 0.370 |
Why?
|
| Cognition Disorders | 1 | 2013 | 370 | 0.310 |
Why?
|
| Dementia | 1 | 2012 | 247 | 0.310 |
Why?
|
| Serotonin | 2 | 2020 | 37 | 0.300 |
Why?
|
| Disease-Free Survival | 7 | 2020 | 326 | 0.300 |
Why?
|
| Necrosis | 3 | 2023 | 51 | 0.300 |
Why?
|
| Electrodes, Implanted | 3 | 2022 | 43 | 0.280 |
Why?
|
| Prognosis | 10 | 2024 | 1547 | 0.270 |
Why?
|
| Neoplasms | 4 | 2020 | 762 | 0.270 |
Why?
|
| Decision Making | 2 | 2020 | 203 | 0.260 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2018 | 40 | 0.250 |
Why?
|
| Reward | 4 | 2024 | 65 | 0.250 |
Why?
|
| Syringomyelia | 1 | 2006 | 3 | 0.240 |
Why?
|
| Glioma, Subependymal | 1 | 2005 | 2 | 0.240 |
Why?
|
| Melanoma | 5 | 2019 | 165 | 0.240 |
Why?
|
| Cerebral Ventricle Neoplasms | 1 | 2005 | 5 | 0.240 |
Why?
|
| Spinal Injuries | 1 | 2006 | 24 | 0.240 |
Why?
|
| Nomograms | 3 | 2015 | 35 | 0.240 |
Why?
|
| Spinal Cord | 1 | 2006 | 121 | 0.220 |
Why?
|
| Multiple Sclerosis | 2 | 2019 | 60 | 0.220 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2024 | 116 | 0.220 |
Why?
|
| Spinal Neoplasms | 1 | 2004 | 22 | 0.220 |
Why?
|
| Genomics | 3 | 2024 | 88 | 0.210 |
Why?
|
| Punishment | 1 | 2023 | 3 | 0.210 |
Why?
|
| Kidney Neoplasms | 2 | 2024 | 205 | 0.200 |
Why?
|
| Voice Disorders | 1 | 2023 | 5 | 0.200 |
Why?
|
| Essential Tremor | 1 | 2023 | 12 | 0.200 |
Why?
|
| Diagnostic Imaging | 1 | 2023 | 97 | 0.190 |
Why?
|
| Postoperative Complications | 3 | 2018 | 828 | 0.190 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2022 | 35 | 0.190 |
Why?
|
| Epilepsy | 1 | 2023 | 83 | 0.180 |
Why?
|
| Cohort Studies | 5 | 2019 | 1852 | 0.180 |
Why?
|
| Disease Progression | 5 | 2024 | 594 | 0.180 |
Why?
|
| Young Adult | 10 | 2020 | 2738 | 0.180 |
Why?
|
| Alcoholism | 1 | 2023 | 102 | 0.180 |
Why?
|
| Hypothalamus | 2 | 2012 | 18 | 0.180 |
Why?
|
| Combined Modality Therapy | 6 | 2022 | 563 | 0.180 |
Why?
|
| Brain Edema | 2 | 2014 | 16 | 0.170 |
Why?
|
| Head and Neck Neoplasms | 1 | 2022 | 134 | 0.170 |
Why?
|
| Radiotherapy | 2 | 2018 | 82 | 0.170 |
Why?
|
| Sulfones | 1 | 2020 | 20 | 0.160 |
Why?
|
| Indans | 1 | 2020 | 34 | 0.160 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2020 | 44 | 0.160 |
Why?
|
| Time Factors | 5 | 2017 | 2195 | 0.160 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 220 | 0.160 |
Why?
|
| Carcinoma | 1 | 2020 | 92 | 0.150 |
Why?
|
| Visual Perception | 1 | 2020 | 116 | 0.150 |
Why?
|
| Survival Rate | 5 | 2020 | 895 | 0.150 |
Why?
|
| Survival Analysis | 5 | 2020 | 486 | 0.150 |
Why?
|
| Adolescent | 8 | 2020 | 3643 | 0.140 |
Why?
|
| Costs and Cost Analysis | 1 | 2018 | 102 | 0.140 |
Why?
|
| Astrocytoma | 1 | 2018 | 29 | 0.140 |
Why?
|
| Feedback, Psychological | 1 | 2018 | 6 | 0.140 |
Why?
|
| Mental Recall | 1 | 2018 | 51 | 0.140 |
Why?
|
| Memory, Short-Term | 1 | 2018 | 60 | 0.140 |
Why?
|
| Recurrence | 2 | 2015 | 282 | 0.130 |
Why?
|
| Psychomotor Performance | 1 | 2018 | 99 | 0.130 |
Why?
|
| Tremor | 2 | 2023 | 12 | 0.130 |
Why?
|
| Medicare | 1 | 2018 | 213 | 0.130 |
Why?
|
| Nervous System Neoplasms | 1 | 2017 | 8 | 0.130 |
Why?
|
| Seizures | 3 | 2023 | 64 | 0.130 |
Why?
|
| Signal Transduction | 1 | 2020 | 689 | 0.130 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2017 | 32 | 0.130 |
Why?
|
| Temporal Lobe | 1 | 2016 | 30 | 0.130 |
Why?
|
| Breast Neoplasms | 3 | 2017 | 754 | 0.120 |
Why?
|
| Treatment Failure | 4 | 2020 | 156 | 0.120 |
Why?
|
| Hypesthesia | 1 | 2015 | 9 | 0.120 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 599 | 0.120 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2018 | 192 | 0.120 |
Why?
|
| Hyperthermia, Induced | 2 | 2016 | 241 | 0.110 |
Why?
|
| Central Nervous System Diseases | 1 | 2015 | 13 | 0.110 |
Why?
|
| Neurofibromatosis 2 | 1 | 2015 | 5 | 0.110 |
Why?
|
| Carmustine | 1 | 2015 | 8 | 0.110 |
Why?
|
| Atrophy | 1 | 2014 | 46 | 0.110 |
Why?
|
| Choice Behavior | 1 | 2015 | 86 | 0.110 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2014 | 7 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 300 | 0.110 |
Why?
|
| Levodopa | 1 | 2014 | 15 | 0.110 |
Why?
|
| Reoperation | 1 | 2015 | 260 | 0.110 |
Why?
|
| Incidence | 4 | 2020 | 1246 | 0.110 |
Why?
|
| Postural Balance | 1 | 2016 | 180 | 0.100 |
Why?
|
| Ecchymosis | 1 | 2013 | 2 | 0.100 |
Why?
|
| Skull Base | 1 | 2013 | 4 | 0.100 |
Why?
|
| Orbital Diseases | 1 | 2013 | 7 | 0.100 |
Why?
|
| Skull Fractures | 1 | 2013 | 17 | 0.100 |
Why?
|
| Pesticides | 1 | 2016 | 196 | 0.100 |
Why?
|
| Neural Pathways | 2 | 2010 | 95 | 0.100 |
Why?
|
| Models, Neurological | 1 | 2014 | 119 | 0.100 |
Why?
|
| Brain Mapping | 2 | 2012 | 179 | 0.100 |
Why?
|
| Pain | 1 | 2015 | 296 | 0.100 |
Why?
|
| Occupational Exposure | 1 | 2016 | 231 | 0.100 |
Why?
|
| Smoking | 1 | 2017 | 531 | 0.100 |
Why?
|
| Craniocerebral Trauma | 1 | 2013 | 58 | 0.100 |
Why?
|
| Affect | 1 | 2013 | 70 | 0.100 |
Why?
|
| Neuropsychological Tests | 2 | 2012 | 363 | 0.100 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 240 | 0.100 |
Why?
|
| Subthalamic Nucleus | 1 | 2012 | 13 | 0.100 |
Why?
|
| Transients and Migrants | 1 | 2016 | 298 | 0.100 |
Why?
|
| Basal Nucleus of Meynert | 1 | 2012 | 1 | 0.090 |
Why?
|
| Pain Measurement | 1 | 2014 | 356 | 0.090 |
Why?
|
| Immunotherapy | 2 | 2024 | 94 | 0.090 |
Why?
|
| Proportional Hazards Models | 4 | 2015 | 765 | 0.090 |
Why?
|
| Craniotomy | 2 | 2017 | 46 | 0.090 |
Why?
|
| Radiotherapy Dosage | 3 | 2017 | 99 | 0.090 |
Why?
|
| Child | 4 | 2020 | 2478 | 0.080 |
Why?
|
| Ventral Thalamic Nuclei | 1 | 2010 | 2 | 0.080 |
Why?
|
| Anterior Thalamic Nuclei | 1 | 2010 | 1 | 0.080 |
Why?
|
| Frontal Lobe | 1 | 2010 | 37 | 0.080 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2010 | 95 | 0.080 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2010 | 37 | 0.080 |
Why?
|
| Electroencephalography | 1 | 2010 | 72 | 0.080 |
Why?
|
| Hispanic Americans | 1 | 2016 | 930 | 0.080 |
Why?
|
| Radiation Dosage | 2 | 2020 | 84 | 0.080 |
Why?
|
| Positron-Emission Tomography | 1 | 2010 | 168 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2019 | 2338 | 0.070 |
Why?
|
| Risk Factors | 4 | 2019 | 4001 | 0.070 |
Why?
|
| Ablation Techniques | 2 | 2018 | 24 | 0.070 |
Why?
|
| Amygdala | 2 | 2019 | 59 | 0.070 |
Why?
|
| Databases, Factual | 2 | 2020 | 369 | 0.070 |
Why?
|
| Pedunculopontine Tegmental Nucleus | 1 | 2007 | 1 | 0.060 |
Why?
|
| Movement Disorders | 1 | 2007 | 26 | 0.060 |
Why?
|
| Cranial Fossa, Posterior | 1 | 2005 | 4 | 0.060 |
Why?
|
| Stereotaxic Techniques | 2 | 2016 | 23 | 0.060 |
Why?
|
| Animals | 4 | 2023 | 7599 | 0.060 |
Why?
|
| Headache | 1 | 2005 | 75 | 0.060 |
Why?
|
| Quality of Life | 2 | 2023 | 976 | 0.060 |
Why?
|
| Mammals | 1 | 2023 | 14 | 0.050 |
Why?
|
| DNA Methylation | 2 | 2015 | 145 | 0.050 |
Why?
|
| Lasers | 1 | 2023 | 24 | 0.050 |
Why?
|
| Motivation | 1 | 2024 | 110 | 0.050 |
Why?
|
| Learning | 1 | 2023 | 80 | 0.050 |
Why?
|
| Immersion | 1 | 2022 | 3 | 0.050 |
Why?
|
| Gelatin | 1 | 2022 | 29 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 682 | 0.050 |
Why?
|
| Neurotransmitter Agents | 1 | 2022 | 26 | 0.050 |
Why?
|
| Hyaluronic Acid | 1 | 2022 | 54 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2022 | 78 | 0.050 |
Why?
|
| Mutation | 1 | 2024 | 499 | 0.050 |
Why?
|
| Hydrogels | 1 | 2022 | 126 | 0.040 |
Why?
|
| Organoids | 1 | 2022 | 98 | 0.040 |
Why?
|
| Collagen | 1 | 2022 | 220 | 0.040 |
Why?
|
| Survivors | 1 | 2022 | 168 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 115 | 0.040 |
Why?
|
| Photic Stimulation | 1 | 2020 | 159 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2020 | 290 | 0.040 |
Why?
|
| Cell Movement | 1 | 2020 | 173 | 0.040 |
Why?
|
| Tissue Scaffolds | 1 | 2022 | 421 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 316 | 0.040 |
Why?
|
| Epilepsy, Tonic-Clonic | 1 | 2019 | 8 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2018 | 99 | 0.040 |
Why?
|
| Karnofsky Performance Status | 1 | 2018 | 11 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2020 | 727 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2020 | 604 | 0.030 |
Why?
|
| Avoidance Learning | 1 | 2018 | 19 | 0.030 |
Why?
|
| Neuronavigation | 1 | 2017 | 8 | 0.030 |
Why?
|
| Tissue Engineering | 1 | 2022 | 659 | 0.030 |
Why?
|
| Hearing Tests | 1 | 2017 | 13 | 0.030 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2017 | 57 | 0.030 |
Why?
|
| Brain Death | 1 | 2017 | 27 | 0.030 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2016 | 10 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2017 | 148 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2016 | 61 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2016 | 73 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2020 | 1282 | 0.030 |
Why?
|
| Disease Management | 1 | 2017 | 128 | 0.030 |
Why?
|
| Retreatment | 1 | 2016 | 40 | 0.030 |
Why?
|
| Biopsy | 1 | 2017 | 245 | 0.030 |
Why?
|
| Games, Experimental | 1 | 2015 | 4 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2017 | 460 | 0.030 |
Why?
|
| DNA Modification Methylases | 1 | 2015 | 11 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2015 | 14 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2015 | 82 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2015 | 70 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2014 | 61 | 0.030 |
Why?
|
| Mice | 1 | 2020 | 2529 | 0.030 |
Why?
|
| Cause of Death | 1 | 2015 | 240 | 0.030 |
Why?
|
| Organ Size | 1 | 2014 | 220 | 0.030 |
Why?
|
| Facial Pain | 1 | 2014 | 21 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2016 | 880 | 0.030 |
Why?
|
| Glucose | 1 | 2014 | 188 | 0.030 |
Why?
|
| Canada | 1 | 2013 | 64 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 194 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2012 | 26 | 0.020 |
Why?
|
| Pain, Postoperative | 1 | 2014 | 193 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 1002 | 0.020 |
Why?
|
| North Carolina | 1 | 2016 | 1550 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2010 | 79 | 0.020 |
Why?
|
| United States | 1 | 2018 | 4132 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2013 | 499 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 950 | 0.020 |
Why?
|
| Cognition | 1 | 2012 | 553 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2010 | 754 | 0.020 |
Why?
|
| Rats | 1 | 2010 | 1610 | 0.020 |
Why?
|